ArticleBMC cancer2026
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study examined the feasibility of a steroid-sparing approach in a dose-dense AC regimen in breast cancer patients, while integrating olanzapine to manage chemotherapy-induced nausea and vomiting (CINV).
methodsA prospective, single-center study was conducted with 30 patients diagnosed with Stage I-III breast cancer who underwent treatment with a dose-dense AC regimen. Patients were given prophylactic olanzapine from days 1 to 4 along with the standard three-drug combination antiemetic regimen, excluding dexamethasone on days 2 and 3. Nausea, vomiting, and drowsiness were evaluated using a validated 4-point Likert scale. The main outcome measured was the complete response (CR) rate in the delayed phase.
resultsThe CR rates were 73% and 63% in the acute and delayed phases, respectively. The total control and complete control rates in the acute phase were 60% and 73%, respectively, while in the delayed phase, they were 36.6% and 63%. Moderate-to-severe daytime sleepiness was observed in 40% of the patients. The mean nausea score on the EORTC QLQ-C30 remained within the minimally important difference threshold for all four treatment cycles.
conclusionThis study suggests that olanzapine may enable steroid reduction without compromising CINV control in patients receiving dose-dense AC. A steroid-sparing regimen could mitigate steroid-related adverse effects while maintaining antiemetic efficacy. Further large-scale studies are warranted to validate these findings and optimize steroid-sparing strategies in antiemetic protocols.
trial registrationThis study was registered on August 29, 2020, in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000041605).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.